Tags

Type your tag names separated by a space and hit enter

Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol.
Eur J Pharmacol. 2005 Nov 21; 525(1-3):74-82.EJ

Abstract

Previous studies have demonstrated that delta9-tetrahydrocannabinol (THC) enhances the antinociceptive potency of many opioids administered by a variety of different routes of administration. We hypothesized that THC would enhance fentanyl or buprenorphine analgesia via the transdermal route of administration. THC was first demonstrated to enhance opioid antinociception when both drugs were administered parenterally in a hairless guinea pig model using the pin prick test. A low dose of THC (50 mg/kg, i.p.) produced no antinociception. However, THC enhanced the potency of s.c. fentanyl by 6.7-fold, and s.c. buprenorphine in a non-parallel fashion. For the transdermal studies, THC, fentanyl or buprenorphine was applied by pipette to the skin of the dorsum between the fore- and hind-flanks and covered with individual Tegederm patches. THC (400 mg/kg) produced no antinociception. However, THC enhanced fentanyl's potency by 3.7-fold at 2-h, and 5.8-fold at 4-h. Buprenophine's potency was increased 8.2-fold at 2-h and 7.2-fold at 4-h when co-administered with THC. These results indicate that the enhancement of transdermal opioids by THC could lead to the design of an effective combination analgesic patch.

Authors+Show Affiliations

Philip Morris, U.S.A., Richmond, VA 23261, United States.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16288738

Citation

Cichewicz, Diana L., et al. "Enhancement of Transdermal Fentanyl and Buprenorphine Antinociception By Transdermal Delta9-tetrahydrocannabinol." European Journal of Pharmacology, vol. 525, no. 1-3, 2005, pp. 74-82.
Cichewicz DL, Welch SP, Smith FL. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. Eur J Pharmacol. 2005;525(1-3):74-82.
Cichewicz, D. L., Welch, S. P., & Smith, F. L. (2005). Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. European Journal of Pharmacology, 525(1-3), 74-82.
Cichewicz DL, Welch SP, Smith FL. Enhancement of Transdermal Fentanyl and Buprenorphine Antinociception By Transdermal Delta9-tetrahydrocannabinol. Eur J Pharmacol. 2005 Nov 21;525(1-3):74-82. PubMed PMID: 16288738.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. AU - Cichewicz,Diana L, AU - Welch,Sandra P, AU - Smith,Forrest L, Y1 - 2005/11/08/ PY - 2005/04/18/received PY - 2005/09/12/revised PY - 2005/09/14/accepted PY - 2005/11/18/pubmed PY - 2006/2/28/medline PY - 2005/11/18/entrez SP - 74 EP - 82 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 525 IS - 1-3 N2 - Previous studies have demonstrated that delta9-tetrahydrocannabinol (THC) enhances the antinociceptive potency of many opioids administered by a variety of different routes of administration. We hypothesized that THC would enhance fentanyl or buprenorphine analgesia via the transdermal route of administration. THC was first demonstrated to enhance opioid antinociception when both drugs were administered parenterally in a hairless guinea pig model using the pin prick test. A low dose of THC (50 mg/kg, i.p.) produced no antinociception. However, THC enhanced the potency of s.c. fentanyl by 6.7-fold, and s.c. buprenorphine in a non-parallel fashion. For the transdermal studies, THC, fentanyl or buprenorphine was applied by pipette to the skin of the dorsum between the fore- and hind-flanks and covered with individual Tegederm patches. THC (400 mg/kg) produced no antinociception. However, THC enhanced fentanyl's potency by 3.7-fold at 2-h, and 5.8-fold at 4-h. Buprenophine's potency was increased 8.2-fold at 2-h and 7.2-fold at 4-h when co-administered with THC. These results indicate that the enhancement of transdermal opioids by THC could lead to the design of an effective combination analgesic patch. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/16288738/Enhancement_of_transdermal_fentanyl_and_buprenorphine_antinociception_by_transdermal_delta9_tetrahydrocannabinol_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(05)00955-6 DB - PRIME DP - Unbound Medicine ER -